(Total Views: 251)
Posted On: 04/29/2025 12:58:59 PM
Post# of 8439
Plantar Fasciitis Market Heats Up
Plantar Fasciitis Pipeline Analysis, Clinical Trials, 2025
"Key Takeaways from the Plantar Fasciitis Pipeline Report
DelveInsight’s Plantar Fasciitis pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Plantar Fasciitis treatment.
The FDA expanded ActiPatch®'s OTC clearance to encompass general musculoskeletal pain, broadening its application beyond specific conditions .
The FDA granted 510(k) clearance for Erchonia's FX 635 low-level laser device for the temporary relief of chronic musculoskeletal pain. This clearance was based on clinical trials demonstrating significant pain reduction in patients.
Key Plantar Fasciitis companies such as Mimedx, Revance Therapeutics, and others are evaluating new drugs for Plantar Fasciitis to improve the treatment landscape.
Promising Plantar Fasciitis therapies are Micronized dHCAM, DAXI, and others."
https://www.barchart.com/story/news/32090432/...erapeutics
Plantar Fasciitis Pipeline Analysis, Clinical Trials, 2025
"Key Takeaways from the Plantar Fasciitis Pipeline Report
DelveInsight’s Plantar Fasciitis pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Plantar Fasciitis treatment.
The FDA expanded ActiPatch®'s OTC clearance to encompass general musculoskeletal pain, broadening its application beyond specific conditions .
The FDA granted 510(k) clearance for Erchonia's FX 635 low-level laser device for the temporary relief of chronic musculoskeletal pain. This clearance was based on clinical trials demonstrating significant pain reduction in patients.
Key Plantar Fasciitis companies such as Mimedx, Revance Therapeutics, and others are evaluating new drugs for Plantar Fasciitis to improve the treatment landscape.
Promising Plantar Fasciitis therapies are Micronized dHCAM, DAXI, and others."
https://www.barchart.com/story/news/32090432/...erapeutics
(1)
(0)
